Palo Capital’s Inovio Pharmaceuticals INO Stock Holding History

Palo Capital’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-1,234	Closed	-$86K	–	137
2015 Q3	$86K	Buy	+1,234	New	+$108K	0.08%	128

Other funds holding INO

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

SIP

Stoneridge Investment Partners Radnor, Pennsylvania $138M AUM 7.66% 1-Year Est. Return

Palo Capital's INO Position: Q4 2015 in Review

Palo Capital sold out of Inovio Pharmaceuticals (INO) in Q4 2015, closing a stake of 1,234 shares — an estimated $86K sold.

Palo Capital first reported a position in INO in Q3 2015 and held it in 1 quarter. The position peaked at $86K in Q3 2015. 123 funds tracked by Wall St. Rank hold INO as of Q4 2015.

Palo Capital reported no remaining Inovio Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Palo Capital sold 1,234 Inovio Pharmaceuticals shares in Q4 2015, an estimated $86K.
Palo Capital first reported a position in Inovio Pharmaceuticals in Q3 2015 and held it in 1 quarter.
Palo Capital's Inovio Pharmaceuticals position peaked at $86K in Q3 2015.
123 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2015.

Based on Palo Capital's 13F filing for Q4 2015, filed 25 Jan 2016.